Pharmaceuticals

Fabry Disease Market Future Drivers Influencing Growth Through 2030

April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Fabry Disease Market In 2026 And 2030?

The Fabry disease market size has experienced robust growth in recent years. It is projected to expand from $2.26 billion in 2025 to $2.43 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.7%. This historic growth can be attributed to heightened awareness of rare genetic disorders, the approval of enzyme replacement therapies, an increase in specialty clinics, the expansion of genetic screening programs, and rising diagnosis rates.

The market for Fabry disease is projected to experience robust expansion over the coming years, anticipated to reach a valuation of $3.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. The projected growth during this period stems from progress in gene-based treatments, the extension of newborn screening initiatives, heightened healthcare expenditure on rare conditions, the proliferation of personalized medicine, and the creation of next-generation oral treatments. Key trends anticipated within the forecast timeframe involve the greater acceptance of enzyme replacement therapy, an intensified focus on diagnosing rare diseases, the expanding application of genetic testing for prompt identification, the broadening availability of oral and supplementary therapies, and the rise of patient-focused treatment methodologies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

Which Major Drivers Are Influencing The Expansion Of The Fabry Disease Market?

An increasing emphasis on personalized medicine is projected to drive the expansion of the fabry disease market moving forward. This treatment approach customizes medical care and therapies for individuals, leveraging information regarding their genes, environment, and lifestyle to achieve superior outcomes. The growing focus on personalized medicine is largely due to its effectiveness in improving treatment and reducing side effects by adapting therapies to individual patient needs. It aids in crafting treatment plans based on a patient’s specific genetic mutation and disease severity, thereby enhancing results and reducing unnecessary side effects. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, noted that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, a significant jump from the six approvals in 2022. Ultimately, this rising focus on personalized medicine is a key driver for the growth of the fabry disease market.

How Is Segmentation Applied In The Fabry Disease Market Segment Analysis?

The fabry disease market covered in this report is segmented –

1) By Type: Type 1, Type 2, Other Types

2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments

3) By Diagnosis: Blood Test, Genetic Test, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease

2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease

3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease

Which Trends Are Shaping The Fabry Disease Market?

Companies operating within the fabry disease market are concentrating on developing advanced treatments, such as PEGylated enzyme replacement therapy (ERT), aiming to boost treatment effectiveness, improve patient compliance, and lessen the immunogenic reactions associated with traditional ERTs. PEGylated enzyme replacement therapy (ERT) itself is a modified version of conventional ERT, where polyethylene glycol (PEG) chains are attached to the enzyme to enhance its stability, extend its circulation time in the body, and reduce immune system responses. As an illustration, in May 2023, Chiesi Global Rare Diseases, a division of the Italy-based pharmaceutical company Chiesi Group, announced that the U.S. Food and Drug Administration (FDA), a US-based government agency, had approved PRX-102 (pegunigalsidase alfa) for use in adult Fabry disease patients. This approval was substantiated by a comprehensive clinical program involving over 140 patients and long-term monitoring for up to 7.5 years, confirming the therapy’s success in reducing renal Gb3 deposits and sustaining kidney function, all while demonstrating a favorable safety profile.

Who Are The Companies Participating In The Fabry Disease Market Environment?

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

Get The Full Fabry Disease Market Report:

https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

Where Is The Fabry Disease Market Primarily Concentrated By Region?

North America was the largest region in the fabry disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Fabry Disease Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

Browse Through More Reports Similar to the Global Fabry Disease Market 2026, By The Business Research Company

Fabry Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report

Gauchers Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report

Carcinoembryonic Antigen Market Report 2026

https://www.thebusinessresearchcompany.com/report/carcinoembryonic-antigen-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795